Combination DMARDs vs Biologic Monotherapy for RA

For most people with rheumatoid arthritis, the standard approach is to start with methotrexate — sometimes on its own, sometimes paired with another conventional drug — and then escalate to a biologic if the first approach falls short. But as biologics and targeted therapies have expanded, the question of whether to combine conventional drugs or go straight to a biologic has become more nuanced. The answer depends on how active your disease is, how long you've had it, what other health conditions you have, and what the latest guidelines actually say.

This article draws on peer-reviewed research from five rheumatologists listed in the Convene directory. Joan Bathon, M.D., at Columbia, published two of the landmark early RA trials comparing biologics against methotrexate. Kenneth Saag, MD, at UAB, co-authored both the 2016 and 2019 EULAR RA treatment guidelines. John Tesser, MD, whose work on cyclosporine plus methotrexate helped define combination conventional therapy for severe RA. Alan Kivitz, MD, co-authored the ORAL Strategy trial — a direct head-to-head comparison of JAK inhibitor monotherapy versus combination therapy. And Charles Ludivico, MD, participated in baricitinib and tocilizumab trials that compared these targeted agents against combination DMARD approaches.

What these treatments actually are

Rheumatoid arthritis is an autoimmune disease where the immune system attacks the lining of the joints. Left untreated, it damages cartilage and bone. The goal of treatment is remission or low disease activity, ideally reached as fast as possible.

Conventional DMARDs (disease-modifying antirheumatic drugs) are older medications — methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide are the main ones. They work broadly across the immune system rather than targeting one specific pathway. Combination csDMARD therapy typically means pairing two or three of these together. The most studied combination is methotrexate plus hydroxychloroquine plus sulfasalazine (sometimes called "triple therapy").

Biologic DMARDs are newer injectable or infused drugs that block specific proteins involved in inflammation. The most widely used target TNF (tumor necrosis factor) — drugs like etanercept, adalimumab, and infliximab. Others block IL-6 (tocilizumab, sarilumab), deplete B cells (rituximab), or block T cell co-stimulation (abatacept). Most biologics are given alongside methotrexate, but some can be given as monotherapy — meaning the biologic alone without methotrexate.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral targeted therapies that work similarly to biologics in mechanism but are taken as pills. They are often grouped with biologics in treatment guidelines and can also be used with or without methotrexate.

At a glance

What early RA trials showed

The question of biologic versus conventional therapy was tested directly in the early 2000s. A 2000 trial in the New England Journal of Medicine compared etanercept to methotrexate in patients with early, active RA [6]. Patients on etanercept had faster symptom reduction and less joint damage on X-ray than those on methotrexate. At one year, etanercept looked better on most measures. A two-year follow-up published in 2002 confirmed that etanercept monotherapy was superior to methotrexate monotherapy for slowing structural damage [7].

But monotherapy comparison is only part of the story. The COMET trial, published in 2004 in Arthritis & Rheumatism, randomized early RA patients to either methotrexate alone or infliximab plus methotrexate [5]. Combination therapy with the biologic and methotrexate produced greater clinical, functional, and radiographic benefit than methotrexate alone. Infliximab plus methotrexate was better than either drug alone.

These trials helped establish that biologics with methotrexate can outperform methotrexate alone. What they did not settle is whether a biologic combination is better than the best conventional combination therapy.

Triple therapy versus biologic: the combination-versus-combination question

The more relevant comparison for patients who have not yet responded adequately to methotrexate is whether to add a second conventional drug or step up to a biologic. John Tesser's 1995 New England Journal of Medicine trial showed that adding cyclosporine to methotrexate in patients with severe RA and partial methotrexate response produced clinically meaningful improvement without a major increase in side effects [9]. A 48-week open-label extension confirmed that the benefit held at one year [for that combination].

Several larger trials have since compared combination csDMARD regimens head-to-head against biologic plus methotrexate combinations. The results have been closer than expected. When conventional drugs are optimized — meaning triple therapy at adequate doses — outcomes for many patients are similar to TNF inhibitor plus methotrexate, particularly for patients with moderate disease activity and no markers of poor prognosis. The major international guidelines have absorbed this finding.

What the EULAR guidelines say

The 2016 EULAR recommendations, co-authored by Kenneth Saag, establish methotrexate as the anchor drug for nearly all RA treatment pathways [1]. If methotrexate fails, the guidelines recommend considering combination csDMARD therapy before moving to biologics, particularly if patients have no markers of poor prognosis such as very high disease activity, early joint damage on imaging, elevated inflammatory markers, or seropositivity (positive rheumatoid factor or anti-CCP antibodies). When poor prognostic markers are present, the guidelines support earlier escalation to a biologic or JAK inhibitor.

The 2019 EULAR update, also co-authored by Saag, preserved this framework while strengthening the role of JAK inhibitors as an equivalent option to biologics after inadequate csDMARD response [2]. It also addressed safety: the updated guidance includes guidance around cardiovascular risk with JAK inhibitors, an issue that became more prominent with longer post-marketing follow-up.

What the ACR guidelines say

The 2021 ACR guidelines, co-authored by Joan Bathon and published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology, align closely with EULAR on the stepwise approach [3][4]. For patients with moderate-to-high disease activity who have not responded adequately to methotrexate, the 2021 ACR guidelines conditionally recommend adding a TNF inhibitor, non-TNF biologic, or JAK inhibitor over switching to another conventional drug. The guidelines acknowledge that combination csDMARD therapy (triple therapy) is a reasonable option for patients who prefer to avoid injectables or for whom cost is a primary concern.

Both guidelines use shared decision-making language: the evidence does not mandate biologics in every case of methotrexate failure, and individual factors matter.

Head-to-head: the ORAL Strategy trial

The ORAL Strategy trial, published in The Lancet in 2017 and co-authored by Alan Kivitz, directly compared three approaches in patients with active RA and inadequate response to methotrexate: tofacitinib monotherapy (a JAK inhibitor alone), tofacitinib plus methotrexate, and adalimumab (a TNF inhibitor) plus methotrexate [8]. This was one of the first trials to put targeted monotherapy against targeted combination therapy in a direct head-to-head design.

Tofacitinib plus methotrexate was non-inferior to adalimumab plus methotrexate on the primary endpoint. Tofacitinib monotherapy was not non-inferior to adalimumab plus methotrexate — meaning JAK inhibitor alone did not match the combination of a biologic with methotrexate. The trial supports methotrexate as an important partner drug even in the era of targeted therapy.

SELECT-NEXT, also co-authored by Kivitz and published in The Lancet in 2018, studied upadacitinib — a more selective JAK inhibitor — in patients with inadequate csDMARD response [11]. Both upadacitinib monotherapy and upadacitinib with background DMARDs outperformed placebo on ACR response and low disease activity endpoints. The trial reinforced that newer JAK inhibitors can work in combination with conventional drugs.

When a biologic is typically recommended earlier

Some patients should not wait to see whether combination csDMARDs work. The 2021 ACR guidelines identify several features that support earlier escalation to a biologic:

• Very high disease activity (high DAS28, CDAI, or SDAI scores)
• Early erosive disease on X-ray or MRI
• High levels of rheumatoid factor or anti-CCP antibody
• Rapidly progressing functional impairment
• Inadequate response to methotrexate at adequate dose for at least 3 months

Baricitinib, studied in patients with refractory RA who had already failed biologics, showed meaningful improvement at 4 mg daily in a 2016 New England Journal of Medicine trial co-authored by Charles Ludivico [10]. This trial enrolled patients who had failed previous biologic treatment — a different, more refractory population — but it illustrates how targeted agents can still produce response even when earlier-line treatment has not worked.

The cost reality

Cost is not a footnote in RA treatment — it is often the central factor in whether a patient can sustain their prescribed regimen. Methotrexate costs a few dollars a month as a generic. Triple therapy (methotrexate, hydroxychloroquine, sulfasalazine) might cost $30–60 per month total, all oral, no refrigeration, no injection.

Biologics are an entirely different price category. Brand-name TNF inhibitors can cost $20,000–$30,000 per year. Biosimilar versions have reduced that cost in recent years, but out-of-pocket exposure can still be substantial depending on insurance. JAK inhibitors are oral, which removes the injection barrier, but their cost is similarly high without good coverage.

The 2019 EULAR and 2021 ACR guidelines both acknowledge that cost and patient preference are legitimate factors in choosing between combination csDMARD and biologic approaches when the clinical picture does not strongly favor one over the other.

Questions to ask your rheumatologist

• Given my disease activity and blood tests, am I in a category where guidelines recommend escalating to a biologic sooner rather than trying combination conventional therapy first?
• If I have not tried triple therapy (methotrexate, hydroxychloroquine, and sulfasalazine together at adequate doses), is that worth attempting before adding a biologic?
• What would you look for over the next 3 months to know whether my current treatment is working well enough?
• With my insurance, what is the realistic out-of-pocket difference between combination conventional drugs and a biologic?
• If I start a biologic or JAK inhibitor, do I need to continue methotrexate alongside it, or can one drug work alone?

The bottom line

For most people with rheumatoid arthritis, methotrexate is the starting point. When it falls short on its own, both combination conventional therapy and escalation to a biologic or JAK inhibitor are evidence-supported paths. Major landmark trials show that TNF inhibitors — particularly combined with methotrexate — can slow joint damage significantly, but optimized triple conventional therapy also performs well for many patients with moderate disease and no high-risk features. Biologics tend to be favored when disease activity is high, erosions are present, or markers of poor prognosis are positive. Cost and patient preference remain legitimate variables in shared decision-making when the clinical picture is ambiguous. The EULAR and ACR guidelines both say to reassess every 1–3 months and adjust the plan if the target is not being reached.